Form 8-K - Current report:
SEC Accession No. 0001193125-23-197818
Filing Date
2023-07-28
Accepted
2023-07-28 17:14:31
Documents
13
Period of Report
2023-07-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d510538d8k.htm   iXBRL 8-K 27656
2 EX-10.1 d510538dex101.htm EX-10.1 92352
  Complete submission text file 0001193125-23-197818.txt   263680

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ffntf-20230725.xsd EX-101.SCH 2532
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ffntf-20230725_lab.xml EX-101.LAB 16683
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ffntf-20230725_pre.xml EX-101.PRE 10428
7 EXTRACTED XBRL INSTANCE DOCUMENT d510538d8k_htm.xml XML 3233
Mailing Address 7010 E. CHAUNCEY LANE STE. 235 PHOENIX AZ 85054
Business Address 7010 E. CHAUNCEY LANE STE. 235 PHOENIX AZ 85054 (602) 633-3067
4Front Ventures Corp. (Filer) CIK: 0001783875 (see all company filings)

EIN.: 834168417 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-56075 | Film No.: 231124098
SIC: 2833 Medicinal Chemicals & Botanical Products